CN1562351A - Application of agglutinin II protein of rhizome of manyflower solmonaeal in pharmacy - Google Patents
Application of agglutinin II protein of rhizome of manyflower solmonaeal in pharmacy Download PDFInfo
- Publication number
- CN1562351A CN1562351A CN 200410022354 CN200410022354A CN1562351A CN 1562351 A CN1562351 A CN 1562351A CN 200410022354 CN200410022354 CN 200410022354 CN 200410022354 A CN200410022354 A CN 200410022354A CN 1562351 A CN1562351 A CN 1562351A
- Authority
- CN
- China
- Prior art keywords
- agglutinin
- rhizoma polygonati
- cell
- hiv
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An application of the polygonalectin II protein is preparing the medicine for preventing and reating hepatitis B and AIDS is disclosed as it can effectively suppress the HepG2.2.1.5 cell to secret antigens HBeAg and HBsAg, and the activity of HIV.
Description
Technical field
The present invention relates to this Chinese herbal medicine of liliaceous plant capsule silk Rhizoma Polygonati (Polygonatum cyrtonema Hua.) is the proteic purposes of Rhizoma Polygonati agglutinin II of feedstock production, the particularly purposes of Rhizoma Polygonati agglutinin II albumen in pharmacy.
Background technology
Agglutinin (Lectin) be the non-enzyme of a class that extensively exists of occurring in nature, non-immunity source, have sugared binding specificity and can make sedimentary albumen of saccharide complex or glycoprotein.Be found to castor bean so far from first phytohemagglutinin, people have found and have separated hundreds of kind agglutinin.
Liliaceous plant capsule silk Rhizoma Polygonati (Polygonatum cyrtonema Hua.) is China's tradition Chinese herbal medicine, Bao Jinku etc. are in " journal of biological chemistry " (the 12nd the 6th phase of volume, in December, 1996) it is that the prepared Rhizoma Polygonati agglutinin II of raw material is to lymphocytic mitogenic activity with plant Rhizoma Polygonati tuber that the paper of delivering on " stability and the biological activity research of Rhizoma Polygonati agglutinin II molecule " discloses a kind of, producing PHA with Guangzhou is contrast, Rhizoma Polygonati agglutinin II to human peripheral lymphocyte's conversion ratio up to 97.6%, the cell division ratio reaches 18.3%, is a kind of extremely strong mitogenesis source.
Hepatitis B is the worldwide viral infectious that is caused by HBV (hepatitis B virus), and it can develop into liver cirrhosis or hepatocarcinoma.According to estimates, the whole world has 300,000,000 people to carry HBV, and just there is the positive carrier of 1.2 hundred million hepatitis B virus surface antigen (HBsAg) in China.Utilize the new anti-HBV medicine of the Chinese herbal medicine resource exploitation of China's abundant significant.
Since 1981 the U.S. find acquired immune deficiency syndrome (AIDS) (acquired immune deficiency syndrome (AIDS), AIDS) since, find that all over the world acquired immune deficiency syndrome (AIDS) or carrier grow with each passing day.The nineteen eighty-three people have determined that AIDS is after being caused by HIV (human immunodeficiency virus) (HIV), thisly cause the disease of significant damage to the mankind for curing, and the whole world is all at the effective anti-HIV medicament of research and development.Developed multiple anti-hiv drug at present, as protease inhibitor, nucleoside analog etc.Therapeutic Method also changes multiple drug regimen mode into by traditional single medicine treatment, but still is difficult to design a kind of long-acting medicine of resisting this retrovirus so far.
Summary of the invention
The object of the present invention is to provide with plant Rhizoma Polygonati tuber is the prepared new application of Rhizoma Polygonati agglutinin II albumen in pharmacy of raw material, so that develop the new medicine that prevents and treat hepatitis B, acquired immune deficiency syndrome (AIDS).
Rhizoma Polygonati agglutinin II of the present invention (PCL II) is a kind of vegetable protein that separation and purification is come out from the plant Rhizoma Polygonati.The separable albumen with strong agglutination activity that is purified into has three kinds from the plant Rhizoma Polygonati: Rhizoma Polygonati agglutinin I (PCL I), Rhizoma Polygonati agglutinin II (PCL II), Rhizoma Polygonati agglutinin III (PCL III), wherein, Rhizoma Polygonati agglutinin II (PCL II) content is maximum.The preparation method of Rhizoma Polygonati agglutinin II (PCL II) has two kinds, a kind of processing step of method is followed successively by " crude product preparation, affinity column separation and purification, the quick column purification of CM-Sepharose ion exchange, molecular sieve purification ", and the processing step of another kind of method is followed successively by " crude product preparation, affinity column separation and purification, molecular sieve purification ".
The present invention proves by experiment: Rhizoma Polygonati agglutinin II (PCL II) albumen has stronger RPHI activity (HBsAg is in conjunction with activity), still has tangible RPHI activity when 7.8ug/ml; Rhizoma Polygonati agglutinin II albumen can effectively suppress the secretion of two kinds of antigen HBeAg of HepG2.2.1.5 cell and HBsAg, when 0.313mg/ml and 0.156mg/ml, suppression ratio to HepG2.2.1.5 emiocytosis HBsAg and HBeAg reaches more than 50%, and cytotoxicity is very little, is a kind of effective anti-hepatitis B virus (HBV) medicine.
The present invention also proves by experiment: Rhizoma Polygonati agglutinin II albumen has very strong inhibitory action to HIV (human immunodeficiency virus) (HIV).When subject cell was HT-4 (mice neurocyte), Rhizoma Polygonati agglutinin II albumen was EC to the half-inhibition concentration of HIV-1
50=0.08ug/ml is EC to the half-inhibition concentration of HIV-2
50=0.08ug/ml; When subject cell is CEM (a t cell lymphoma cell), Rhizoma Polygonati agglutinin II albumen is respectively EC to the half-inhibition concentration of HIV-1 and HIV-2
50=0.05ug/ml and EC
50=0.10ug/ml, lower 10-100 times than the half-inhibition concentration of other mannose binding lectin, promptly suppress HIV normal cell infection activity is exceeded other mannose binding lectin 10-100 doubly.And Rhizoma Polygonati agglutinin II is respectively CC to the half cytotoxicity concentration of HT-4 and CEM
50=73ug/ml and CC
50=74ug/ml also exceeds nearly 10 times than other agglutinin, demonstrates very high HIV (human immunodeficiency virus)-resistant activity and very low toxicity.
Therefore, Rhizoma Polygonati agglutinin II protein Preparation can be become the medicine of treatment or prevention hepatitis B virus (HBV) and HIV (human immunodeficiency virus) (HIV) associated diseases, administrated method can be by oral, intravenous injection etc.
The present invention has following beneficial effect:
1, the present invention has excavated new medical application for Rhizoma Polygonati agglutinin II albumen, for serious threat human life's hepatitis B and the prevention and the treatment of acquired immune deficiency syndrome (AIDS) provide new medicine.
2, the pharmacological action of Rhizoma Polygonati agglutinin II albumen is strong and toxicity is very low, is indicating well prospect in medicine.
3, the proteic raw material of preparation Rhizoma Polygonati agglutinin II---plant Rhizoma Polygonati tuber source is wide, and the proteic technology of preparation Rhizoma Polygonati agglutinin II is simple, thereby is convenient to suitability for industrialized production, helps reducing preparation cost.
Description of drawings
Fig. 1 is the proteic SDS-PAGE electrophoretogram of Rhizoma Polygonati agglutinin II of the present invention.
The specific embodiment
Embodiment 1: the proteic preparation of Rhizoma Polygonati agglutinin II
In the present embodiment, the proteic preparation method of Rhizoma Polygonati agglutinin II is as follows:
1, crude product preparation
To be cut into flaky Rhizoma Polygonati tuber with normal saline solution leaching (G/V=1: 5) spend the night, mash through high-speed tissue mashing machine, the normal saline solution leaching is spent the night, filtered through gauze, centrifugal (4 ℃, 4500r/min, 30min), in supernatant, add solid ammonium sulfate and reach 30% saturation, put 4 ℃ and spend the night, centrifugal (4 ℃, 4500r/min, 30min) go precipitation, supernatant continues to add ammonium sulfate to 90%, centrifugal collecting precipitation, and precipitation is dissolved in distilled water, the dialysis desalination, lyophilization gets Rhizoma Polygonati agglutinin crude product.
2, affinity column separation and purification
Get crude product 200mg and be dissolved in the 20ml normal saline solution, dialysis equilibrium, the centrifugal insoluble matter of removing is got supernatant and is carried out affinity chromatograph (post: 2.6 * 40cm).With mannose-Sepharose 4B is affinity adsorbent, behind physiological solt solution balance chromatographic column, with above-mentioned agglutinin crude product upper prop, identical physiological solt solution be eluted to effluent in 280nm place absorption value less than 0.02, use 0.2mol/L mannose solution desorption instead, fraction collection all in eluting and the desorption process, flow velocity 18ml/hr, the 3-4ml/ pipe, collecting pipe is after the 280nm place measures uv absorption, with the sample normal saline dialysis, with the agglutination activity of rabbit erythrocyte sample for reference, merge active part and dialyse and desalt, lyophilization gets the affinity chromatograph sample.
3, molecular sieve purification
Learn from else's experience the Sephacryl S-100 dress post handled (1.6 * 100cm), use the normal saline balance.With above-mentioned affinity chromatograph sample with physiological solt solution dissolving and dialysis equilibrium after upper prop, use the same solution eluting, fraction collection, flow velocity are 2ml/min, 3ml/tube, after the 280nm place measures uv absorption and detection of active, collect active part, the dialysis desalination, lyophilization obtains the Rhizoma Polygonati agglutinin II of purification, detect to single protein component through SDS-PAGE, see Fig. 1.
Embodiment 2: the proteic preparation of Rhizoma Polygonati agglutinin II
In the present embodiment, the proteic preparation method of Rhizoma Polygonati agglutinin II is as follows:
1, crude product preparation
(G/V=1: 5) spend the night, mash through high-speed tissue mashing machine, the normal saline solution leaching is spent the night with the normal saline solution leaching will to be cut into lamellar and air dried Rhizoma Polygonati tuber, filtered through gauze, centrifugal (4 ℃, 4500r/min, 30min), in supernatant, add solid ammonium sulfate and reach 30% saturation, put 4 ℃ and spend the night, the centrifugal precipitation of going of the same method, supernatant continues to add ammonium sulfate to 90%, centrifugal collecting precipitation, and precipitation is dissolved in distilled water, the dialysis desalination, lyophilization gets Rhizoma Polygonati agglutinin crude product.
2, affinity column separation and purification
Get crude product (200mg) and be dissolved in the 20ml normal saline solution, dialysis equilibrium, the centrifugal insoluble matter of removing is got supernatant and is carried out affinity chromatograph (post: 2.6 * 40cm).With pig thyroglobulin-Sepharose 4B is affinity adsorbent, behind physiological solt solution balance chromatographic column, with above-mentioned agglutinin crude product upper prop, identical physiological solt solution be eluted to effluent in 280nm place absorption value less than 0.02, it is attached to use 0.2mol/L HAC solution stripping instead, fraction collection all in eluting and the desorption process, flow velocity 18ml/hr, 3-4ml/ pipe, collecting pipe are after 280nm place measures uv absorption, and it is (first with 5% NaHCo to check that with rabbit erythrocyte collecting pipe gets agglutination activity
3In and desorption part collecting pipe), merge active part and dialysis is desalted, lyophilization gets the affinity chromatograph sample.
3, the quick column purification of CM-Sepharose ion exchange
The quick post dress of the CM-Sepharose ion exchange post (2.6 * 28cm) of learning from else's experience and handling, use pH4.0,0.02mol/L NaAC-HAC buffer balance, affine sample (100mg) is dissolved in the 20ml same buffer, the centrifugal insoluble matter of removing is also gone up the CM-Sepharose post, with identical buffer solution elution to effluent in 280nm place absorption value less than 0.02, the NaCl that uses 0.6mol/L instead carries out the continuous ionic gradient elution, fraction collection (3ml/min, the 3-4ml/ pipe), collecting pipe is after 280nm measures, and rabbit erythrocyte checks that agglutination activity is (earlier with 5% NaHCo
3In and desorption part collecting pipe), merge active part, dialysis desalination and lyophilization get the ion-exchange chromatography sample.
4 molecular sieve purification
Learn from else's experience the Sephadex G-100 dress post handled (1.6 * 100cm), use the normal saline balance.With above-mentioned CM-Sepharose post sample with physiological solt solution dissolving and dialysis equilibrium after upper prop, use the same solution eluting, fraction collection, flow velocity are 12ml/hr, 3ml/tube, after the 280nm place measures uv absorption and detection of active, collect active part, the dialysis desalination, lyophilization obtains the Rhizoma Polygonati agglutinin II of purification, detect to single protein component through SDS-PAGE, see Fig. 1.
Embodiment 3: Rhizoma Polygonati agglutinin II albumen (PCL II) is to the inhibitory action of hepatitis B (HBV) virus
1, material and method
1.1 material
Rhizoma Polygonati agglutinin II albumen (PCL II) adopts embodiment 1 or embodiment 2 described method preparations, is used for cytotoxicity and anti-hepatitis B determination of activity behind serial doubling dilution.
Lyophilizing HBsAg preparing Diagnostic Erythrocyte: Shanghai industry section China biological engineering company limited.
Recombination yeast Hepatitis B virus vaccine (HBsAg): Beijing Biological Product Inst., Ministry of Public Health's product.
HepG2.2.1.5 cell: Medical University Of Chongqing's cell strain that hepatitis research provides.HBsAg, HBeAg detection kit: Fourth Ring, Beijing bioengineering product factory product.
Culture medium: RPMI-1640 (GIBCO product) is according to the explanation dissolving, be adjusted to pH7.2, filtration sterilization, add hyclone (GIBCO product, the import packing) to concentration be 10%, contain 100U/ml penicillin (Chongqing Yaoyou Pharmaceutical Co., Ltd.), 100 μ g/ml streptomycin sulfates (Shanghai four medicine limited companies) and 0.2mg/ml G418 (GIBCO product).
Trypsin: GIBCO product; Phosphate buffer (PBS): be Na
2HPO
4And NaH
2PO
4The aqueous solution of the concentration 0.02M that is mixed with, pH=7.0 sterilized 30 minutes for 121～126 ℃, and 4 ℃ of refrigerator preservations are standby, and used chemical drugs is homemade analytical reagent.
MTT:3-(4,5)-two methyl-second-thiazole-(2,5)-dimethyl bromination tetrazole indigo plant, the Sigma product.
96 orifice plates: Nunclon product; Microplate reader: Model 550, the Bio-Red product.
Acycloguanosine injection (ACV): beneficial pharmaceutcal corporation, Ltd of beautiful pearl Hubei section of group product.
Heptodin (Heptin): lamivudine, (2R-cis) 4-amino-1-(2-methylol-1,3-oxygen thia ring penta-5-yl)-1-H-pyrimid-2-one, Britain Glaxo Welcome company product.
1.2 method
1.2.1 anti-phase passive blood coagulation inhibition experiment (RPHI, Zheng Minshi, Li Hua, Han Yiping etc., 100 kinds of Chinese herbal medicine are to the inhibiting observation of hepatitis B virus surface antigen. Chinese herbal medicine, 1987 the 18th the 10th phases of volume: 27～29; Zheng Minshi, Zhang Jingen, Liu Zhiyong etc., the experimentation of 200 kinds of Chinese herbal medicine anti-HBsAgs of elisa technique screening. JOURNAL OF MICROBIOLOGY, 1996 01 phases: 1～4; Zheng Minshi, Li Wen, Li Rong, Zhang Jingen etc. use the effect of 270 kinds of Chinese herbal medicine anti-HBsAgs of elisa technique screening. traditional Chinese medical science research, 1996,9 (1): 51～54.) measure the HBsAg of Rhizoma Polygonati agglutinin II in conjunction with activity
In each hole of 96 orifice plates, add 25 microlitre blood cell diluents, in first hole, add 25 microlitres Rhizoma Polygonati agglutinin to be measured II samples (1mg/ml), carry out serial doubling dilution, the vibration mixing.Add 25 microlitre Hepatitis B virus vaccine (HBsAg) solution in every hole, the vibration mixing was put into 37.0 ℃ of constant temperature, constant humidity incubator incubation 4 hours.Use 5ml blood cell diluted lyophilizing HBsAg preparing Diagnostic Erythrocyte simultaneously, put into incubator activation 1 hour.Every hole of 96 orifice plates adds 50 microlitre preparing Diagnostic Erythrocyte suspensions then, puts into the incubator incubation 1 hour, takes out and observes the blood coagulation result.Sample detects for three times repeatedly, determines its activity.Negative control (blood coagulation fully): 25 microlitre blood cell diluents, 25 microlitre HBsAg solution, 50 microlitre preparing Diagnostic Erythrocyte suspensions; Positive control (not having blood coagulation): 50 microlitre blood cell diluents, 50 microlitre preparing Diagnostic Erythrocyte suspensions; Medicine positive control: 25 microlitre blood cell diluents, 25 microlitre Radix Astragali lixiviating solution doubling dilutions, 25 microlitre HBsAg solution, 50 microlitre preparing Diagnostic Erythrocyte suspensions.
1.2.2 the anti-HBV activity research of Rhizoma Polygonati agglutinin II on the HepG2.2.1.5 cell
1.2.2.1 HepG2.2.1.5 cell culture
Get the HepG2.2.1.5 cell that a pipe liquid nitrogen is preserved, place 37 ℃ of tepidarium quick-thawings (dissolving fully in 1 minute), transfer in the 5ml fresh culture, mixing, centrifugal 10 minutes of 1000rpm, supernatant discarded (removing the DMSO in the freeze-stored cell suspension), add culture medium 5ml, change over to behind the mixing in the culture bottle, 37 ℃, 5%CO
2Be cultured to monolayer in the incubator, the branch flask culture goes down to posterity.
1.2.2.2 Rhizoma Polygonati agglutinin II is to the cytotoxicity and the anti-HBV activity research of HepG2.2.1.5 cell
With Rhizoma Polygonati agglutinin II sample dissolution, be made into 1mg/ml with culture medium, doubling dilution becomes some concentration, and-20 ℃ of preservations are standby.After the HepG2.2.1.5 cell grows up to monolayer, it is inferior to give a baby a bath on the third day after its birth with phosphate buffer PBS, each 4～5ml adds the about 2ml of 0.25% trypsin solution, is digested to unicellular, add culture medium 6ml, centrifugal 10 minutes of 1000rpm, supernatant discarded adds culture medium and vibrates into cell suspension, carry out cell counting, regulating cell concentration with culture medium is 1 * 10
5Cells/ml.Inoculate the HepG2.2.1.5 cell then in 96 orifice plates, every hole 0.2ml, 37 ℃, 5%CO
2After being cultured to monolayer in the incubator, inhaling and to go culture medium, add contain the variable concentrations sample culture medium, each concentration is established four multiple holes, the cell blank group adds fresh culture.Cultivate after four days, get cells and supernatant ,-20 ℃ of preservations add the fresh culture medium that contains sample, continuous culture 12 days, and sampling in per four days is once.After the last sampling, every hole adds the dissolved MTT solution of 0.5mg/ml fresh culture 0.2ml, places 37 ℃, 5%CO
2Continue in the incubator to cultivate 4 hours, inhale gently then and remove supernatant solution, every hole adds dimethyl sulfoxine (DMSO) 200 μ l, 5min vibrates on agitator, use dual wavelength (570nm is for measuring wavelength, and reference wavelength is 630nm) method to measure absorbance O.D value then, calculate cell survival rate.
Detect antigenic tiring in HBeAg test kit and the one-step ELISA detection HBsAg kit measurement cells and supernatant with one-step ELISA, the result estimates according to operation instruction on the test kit, it is 2.1 positive that antigen valence S/N is greater than or equal to, antigen valence S/N is negative less than 2.1, according to the suppression ratio of test kit description calculation sample to HBeAg and HBsAg, the anti-HBV activity of assess sample.
2 results and discussion
2.1 anti-phase passive blood coagulation suppresses experiment (RPHI)
The RPHI activity of table 1 Rhizoma Polygonati agglutinin II (PCLII)
Lectin?Concentration(μg/mL)
Cell
500????250?????125?????62.5???31.25??15.6???7.8???3.9??1.95??0.95???0.49
RPHI??????++++???++++????+++?????+++????++?????++?????+-????-????-?????-??????-
Annotate: " +++" represent that the RPHI activity is very strong, " ++ " expression RPHI activity is stronger, and RPHI is obviously active in "+" expression, and " ± " represents that the RPHI activity is not obvious.
Rhizoma Polygonati agglutinin II (PCL II) has stronger RPHI activity (HBsAg is in conjunction with activity) as can be found from Table 1, still has tangible RPHI activity when 7.8ug/ml.Show that Rhizoma Polygonati agglutinin II has anti-hepatitis B virus activity.Its active height can be by measuring the cytotoxicity experiment of HepG2.2.1.5 cell and the secretion of inhibition two kinds of antigen HBeAg of HepG2.2.1.5 cell and HBsAg.
2.2 Rhizoma Polygonati agglutinin II sample is to the cytotoxicity and the anti-HBV activity of HepG2.2.1.5 cell
Get heptodin a slice, pulverize, with the solution of cultivating basigamy 2.5mg/ml, ACV and Rhizoma Polygonati agglutinin II also are made into the solution of 2.5mg/ml with culture medium, filtration sterilization ,-20 ℃ of preservations behind the doubling dilution.After treating that the HepG2.2.1.5 cell grows up to monolayer on 96 orifice plates, culture medium is gone in suction, add the fresh culture that contains the variable concentrations sample, four multiple holes of each concentration, changed the fresh culture that contains the same concentrations sample in per 4 days, cultivated 12 days, after culture medium was gone in suction, mtt assay (was seen CamplingBG, Pym J, Baker HM, Cole SP, Lam YM.Chemosensitivity testing of small cell lung cancerusing the MTT assay.Br J Cancer, 1991,63 (1): 75-83.) measure cell survival rate, the results are shown in Table 2: as can be seen from Table 2, under each concentration of heptodin, cell survival rate has surpassed 100% more in the time of the 12nd day, apparently higher than blank cell matched group, so heptodin is very little to the toxicity of HepG2.2.1.5 cell; Cell survival rate from the 12 day, can find that ACV has significant cytotoxicity during more than or equal to 0.625mg/ml in concentration, when ACV is 2.5mg/ml and 1.25mg/ml in concentration, the survival rate of cell is respectively 12.83% and 14.83%, cell quantity is significantly less than blank cell contrast, can see having large stretch of cell death to come off at microscopically, cell survival rate is lower than 50%, and the cytotoxicity of ACV is bigger.And the cytotoxicity of Rhizoma Polygonati agglutinin II is very low, and pair cell is nontoxic substantially under the concentration of 2.5mg/ml, and cell survival rate all remains on more than 96%.
In order further to study heptodin, ACV and Rhizoma Polygonati agglutinin II inhibitory action to HepG2.2.1.5 emiocytosis HBsAg and HBeAg, detect tiring of HBsAg and HBeAg with the reagent corresponding box, and calculate suppression ratio, the results are shown in Table 3.Heptodin (lamivudine) although cytotoxicity is low, can not effectively suppress HepG2.2.1.5 emiocytosis HBeAg and HBsAg as a kind of active drug for the treatment of hepatitis B clinically.Under the concentration of 2.5mg/ml, HBsAg and HBeAg suppression ratio are respectively 35.8% and 47.24%.
The survival rate of the 12nd day cell of table 2
Concentration (mg/ml) 2.5 1.25 0.625 0.313 0.156 0.078 0.039
Heptodin % 153.32 156.35 171.92 141.87 131.94 132.10 95.57
ACV％???????12.83?????14.83????38.81?????79.36????81.53?????81.55????81.97
PCLII％?????96.55?????98.33????98.26?????98.56????97.37?????98.72????99.58
Table 3 the 12nd day heptodin, ACV and Rhizoma Polygonati agglutinin II are to the inhibitory action of HBsAg and HBeAg
| Concentration (mg/ml) | ??2.5 | ??1.25 | ??0.625 | ??0.313 | ??0.156 | ????0.078 | ||
| Heptodin | HBsAg | ??S/N | ??1.313 | ??1.537 | ??1.493 | ??1.418 | ??1.433 | ????2.581 |
| Suppression ratio % | ??35.8 | ??24.8 | ??23.17 | ??-21.8 | ??-23.1 | ????-11.6 | ||
| HBeAg | ??S/N | ??7.233 | ??2.524 | ??4.152 | ??5.405 | ??8.076 | ????7.295 | |
| Suppression ratio % | ??47.24 | ??85.19 | ??72.07 | ??61.97 | ??40.45 | ????46.74 | ||
| ?ACV | HBsAg | ?S/N | ??2.829 | ??3.738 | ????1.875 | ??2.080 | ????2.370 | ??1.641 |
| Suppression ratio % | ??80.25 | ??72.34 | ????21.57 | ??-13.25 | ????-38.92 | ??-56.39 | ||
| HBeAg | ?S/N | ??2.523 | ??5.326 | ????1.693 | ??1.373 | ????1.875 | ??2.356 | |
| Suppression ratio % | ??86.24 | ??65.83 | ????26.36 | ??-18.3 | ????-45.90 | ??-76.32 | ||
| ?PCLII | HBsAg | ?S/N | ??2.432 | ??2.812 | ????5.522 | ??5.824 | ????1.837 | ??1.549 |
| Suppression ratio | ??85.78 | ??80.86 | ????64.37 | ??50.32 | ????32.16 | ??26.87 | ||
| HBeAg | ?S/N | ??3.045 | ??2.436 | ????3.633 | ??5.532 | ????5.823 | ??3.236 | |
| Suppression ratio | ??89.89 | ??84.35 | ????76.35 | ??67.68 | ????50.12 | ??35.67 |
The experimental result of table 3 shows that heptodin can suppress duplicating of HBV-DNA, and to HBeAg and the excretory inhibitory action of HBsAg and inconsistent.When ACV is 2.5mg/ml and 1.25mg/ml in concentration, the 12nd day HBeAg suppression ratio has reached 86.24% and 65.83%, this toxicity with ACV is relevant, because under these two concentration, the survival rate of cell is respectively 12.83% and 14.83%, cell quantity is significantly less than blank cell contrast (seeing Table 2), thus the antigen of emiocytosis must reduce greatly, so ACV does not have the obvious suppression effect to HBeAg and HBsAg yet.Rhizoma Polygonati agglutinin II can effectively suppress the secretion of two kinds of antigen HBeAg of HepG2.2.1.5 cell and HBsAg, when 0.313mg/ml and 0.156mg/ml, suppression ratio to HepG2.2.1.5 emiocytosis HBsAg and HBeAg reaches more than 50%, and cytotoxicity very little (see Table 2, table 3), be a kind of effective anti-hepatitis B virus (HBV) medicine.
Though the HepG2.2.1.5 cell is an extracorporeal experiment system, broken away from the environment that immune system exerts an influence to HBV in the body, this cell model provides scientific basis for comprehensively, accurately estimating the anti-HBV effect of medicine.
Embodiment 4: Rhizoma Polygonati agglutinin II albumen (PCL II) is to the inhibitory action of HIV (human immunodeficiency virus) (HIV)
1 experiment material and method
1.1 material
Galanthus Nivalis Agglutinin (GNA) (Galanthus nivalis agglutinin, GNA), Herba Convallariae agglutinin (Scilla campanulataagglutinin, SCA), the orchid agglutinin (Listera Ovta lectin, LOL) sample is provided by the Van Damme of university of Luwen plant protection institute professor laboratory; (Lycoris radiataAgglutinin LRA) is provided by Sichuan University biomaterial center lycoris agglutinin; Rhizoma Polygonati agglutinin II (PCLII) albumen is by embodiment 1 or embodiment 2 described method preparations.
HIV (human immunodeficiency virus) (Human Immunodeficiency Virus) strain: HIV-1 and HIV-2 are preserved by Ri Jia Institute for Medical Research.
Normal cell strain: CEM (t cell lymphoma cell line) and TH-4 (mice neuronal cell line) are the cultivation of going down to posterity of Ri Jia Institute for Medical Research.
1.2 method
The active mensuration of Rhizoma Polygonati agglutinin II anti AIDS virus adopts the experimental technique of Balzarini (to see Balzrini J, Naesens L, Herdewijn P, Rosenberg I, Holy A, Pauwels R, Baba M, Johns DG, De Clercq I, Marked in vivo anti-retrovirus activity of PMEA[9-(2-phosphonylmethoxyethyl) adenine], anew selective anti-HIV agent, Proc Natl Acad Sci USA, 1989,86:332-336; Balzarini J, Aaesens L, Slachmuylders J, Niphuis H, Rosenberg I, Holy A, Schellekens H, De Clercq E, [9-(2-phosphonylmethoxyethyl) adenine] be effectively inhibits retrovirus replication invitro and simian immunodeficiency virus infection in Rhesus monkeys (PMEA), AIDS, 1991,5:21-28): the EC that measures PCLII respectively
50(503nhibiting concentration) and CC
50(to the half cytotoxicity concentration of subject cell).Used cell strain is CEM (t cell lymphoma cell line) and TH-4 (mice neuronal cell line); HIV (human immunodeficiency virus) (Human Immunodeficiency Virus) is HIV-1 and HIV-2 Strain, control sample is Galanthus Nivalis Agglutinin (GNA) (Galanthus nivalis agglutinin, GNA), lycoris agglutinin (Lycoris radiata Agglutinin, LRA), and the Herba Convallariae agglutinin (Scilla campanulata agglutinin, SCA), the orchid agglutinin (Listera Ovta lectin, LOL).
CEM and TH-4 cell suspension are in fresh culture (4 * 10
5Cells/ml), with 100 times of CCID
50HIV-I and the HIV-II of/ml (cellculture infective dose 50) infect (1 CCID
50Be 50% cultured cell required viral dosage when infected).Then, the cell suspension that infects of 100ul move into micro-serum dilution plate and 100ul after the Rhizoma Polygonati agglutinin II of serial doubling dilution and other sample mix in 37 ℃ of cultivations.Detect the formation of syncytial virus capsule in the infected cell culture fluid after 4 days.Antiviral activity EC
50(effective concentration 50) expression, i.e. half required Rhizoma Polygonati agglutinin II concentration when suppressing syncytial virus capsule by the HIV mediation and forming; Cytotoxicity CC
50(cytotoxicconcentration 50) expression, the i.e. required Rhizoma Polygonati agglutinin II concentration of 50% cultured cell generation pathological changes.
2 results and discussion
Table 4 Rhizoma Polygonati agglutinin II albuminous cell toxicity and HIV (human immunodeficiency virus)-resistant activity
EC
50(μg/ml)
HT-4?????????????CEM?????????????CC
50(μg/ml)
HIV-1????HIV-2???HIV-1???HIV-2????????HT-4????CEM
PCL?II???0.08?????0.08????0.05????0.10?????????73??????74
GNA??????0.76.????0.68????0.92????0.78?????????6.5?????6.9
LRA??????0.43?????0.60????0.79????0.59?????????71??????71
SCA??????5.0??????9.0?????4.60????8.0??????????80??????83
LOL??????0.5??????0.5?????0.46????0.55?????????8.6?????7.9
Rhizoma Polygonati agglutinin II the results are shown in Table 4 to HIV-1 and HIV-2 resistance, and as shown in Table 4, Rhizoma Polygonati agglutinin II albumen has very strong inhibitory action to HIV.When subject cell was HT-4 (mice neurocyte), Rhizoma Polygonati agglutinin II was EC to the half-inhibition concentration of HIV-1
50=0.08ug/ml is EC to the half-inhibition concentration of HIV-2
50=0.08ug/ml; When subject cell is CEM (a t cell lymphoma cell), Rhizoma Polygonati agglutinin II is respectively EC to the half-inhibition concentration of HIV-1 and HIV-2
50=0.05ug/ml and EC
50=0.10ug/ml, lower 10-100 times than the half-inhibition concentration of other mannose binding lectin, promptly suppress HIV normal cell infection activity is exceeded other mannose binding lectin 10-100 doubly.And Rhizoma Polygonati agglutinin II is respectively CC to the half cytotoxicity concentration of HT-4 and CEM
50=73ug/ml and CC
50=74ug/ml.Also exceed nearly 10 times, demonstrate very high HIV (human immunodeficiency virus)-resistant activity and very low toxicity than other agglutinin.SCA is that Recent study gets comparatively clearly unifacial leaf mannose binding lectin, and its space structure is also illustrated, and particularly its anti-AIDS cytotoxic activity has caused many scholars' concern [Pierre Rizkallah, " Bluebells; Daffodils may be used in AIDS drugs ", BritishResearchers Report New Findings, 2002].This experimental result shows that anti-HIV-1 and the HIV-2 activity of Rhizoma Polygonati agglutinin II exceed 60 times and 100 times than SCA respectively.The reason that the activity of Rhizoma Polygonati agglutinin II obviously exceeds other unifacial leaf mannose binding lectin may be Rhizoma Polygonati agglutinin II except that can be in conjunction with the mannose, can also bound sialic acid, and be a kind of sialic acid and mannose binding lectin.Studies show that, the gp120 sugar chain of HIV also contains sialylated glycosyl except that containing mannose, infer Rhizoma Polygonati agglutinin II except that with the mannose group of gp120 in conjunction with, also in conjunction with the sialic acids groups of gp120, thus more effective sealing and blocking-up gp120 and host cell surface CD
4Identification and combination, demonstrate the effect that stronger inhibition HIV infects, show that also Rhizoma Polygonati agglutinin II is that a kind of HIV efficiently infects and suppresses carbohydrate-binding protein.
Claims (4)
1, the application of Rhizoma Polygonati agglutinin II albumen in the medicine of preparation treatment or prevention hepatitis B.
2, application according to claim 1 is characterized in that the hepatitis B that institute treats or prevents is caused by viral HBeAg, HBsAg.
3, the application of Rhizoma Polygonati agglutinin II albumen in the medicine for preparing treatment or prevent AIDS.
4, application according to claim 3 is characterized in that the acquired immune deficiency syndrome (AIDS) that institute treats or prevents is caused by HIV (human immunodeficiency virus) HIV-1, HIV-2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022354 CN1269526C (en) | 2004-04-20 | 2004-04-20 | Application of agglutinin II protein of rhizome of manyflower solmonaeal in pharmacy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022354 CN1269526C (en) | 2004-04-20 | 2004-04-20 | Application of agglutinin II protein of rhizome of manyflower solmonaeal in pharmacy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100055777A Division CN100388948C (en) | 2004-04-20 | 2004-04-20 | Application of polygonatum cyrtonema Hua. Lectin II protein in medicine preparation for treating or preventing AIDS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1562351A true CN1562351A (en) | 2005-01-12 |
| CN1269526C CN1269526C (en) | 2006-08-16 |
Family
ID=34480056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410022354 Expired - Fee Related CN1269526C (en) | 2004-04-20 | 2004-04-20 | Application of agglutinin II protein of rhizome of manyflower solmonaeal in pharmacy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1269526C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113121665A (en) * | 2021-03-26 | 2021-07-16 | 四川大学 | Two modified high-efficiency low-immunogenicity sealwort agglutinin proteins |
| CN115137806A (en) * | 2021-03-30 | 2022-10-04 | 四川大学 | Application of Polygonatum cyrtonema lectin in blocking invasion and infection of novel coronavirus |
| WO2023245415A1 (en) * | 2022-06-21 | 2023-12-28 | 四川大学 | Use of polygonatum cyrtonema hua. lectin in blocking invasion and infection of novel coronavirus |
-
2004
- 2004-04-20 CN CN 200410022354 patent/CN1269526C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113121665A (en) * | 2021-03-26 | 2021-07-16 | 四川大学 | Two modified high-efficiency low-immunogenicity sealwort agglutinin proteins |
| CN113121665B (en) * | 2021-03-26 | 2023-03-10 | 四川大学 | Two modified low-immunogenicity sealwort agglutinin proteins |
| CN115137806A (en) * | 2021-03-30 | 2022-10-04 | 四川大学 | Application of Polygonatum cyrtonema lectin in blocking invasion and infection of novel coronavirus |
| CN115137806B (en) * | 2021-03-30 | 2023-07-07 | 四川大学 | Use of rhizoma Polygonati lectin in blocking invasion and infection of novel coronavirus |
| WO2023245415A1 (en) * | 2022-06-21 | 2023-12-28 | 四川大学 | Use of polygonatum cyrtonema hua. lectin in blocking invasion and infection of novel coronavirus |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1269526C (en) | 2006-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101669979A (en) | Artemisia scoparia extractive and production method and applications thereof | |
| CN101744805B (en) | Use of amentoflavone biflavone as only active component in curing viral diseases | |
| Li et al. | Anti-hepatitis activities in the broth of Ganoderma lucidum supplemented with a Chinese herbal medicine | |
| CN102552369B (en) | Lon icera japonica Thunb leaf extractive serving as anti-porcine reproductive and respiratory syndrome viral agent | |
| CN101695511B (en) | Pomegranate rind extract and production method and application thereof | |
| CN1269526C (en) | Application of agglutinin II protein of rhizome of manyflower solmonaeal in pharmacy | |
| CN101912425A (en) | Ginkgo episperm extract with antitumor and immunostimulating activity and preparation method of effective part thereof | |
| CN100388948C (en) | Application of polygonatum cyrtonema Hua. Lectin II protein in medicine preparation for treating or preventing AIDS | |
| CN102755355B (en) | Drug composition resisting influenza virus A or enterovirus | |
| CN105560352A (en) | Duck viral hepatitis resisting astraglus polysaccharide phosphorylated molecular modification method | |
| CN1250240C (en) | Isatis root extract, and preparing method and use thereof | |
| AU629855B2 (en) | Therapeutic agent for aids and process for preparing it | |
| CN1864725A (en) | Method for extracting active ingredient of starofbethlehem and use thereof | |
| CN1269525C (en) | Agglutinin II protein of rhizome of king solomonseal, and application | |
| CN1261143C (en) | Separating preparation process of effective part and active component of influenza virus resisting medicine | |
| CN1579467A (en) | Anti-virus medicine | |
| CN102670684B (en) | Application of cynanchum atratum total saponin | |
| CN1883619A (en) | Pharmaceutical composition of viola yedoensis and method for preparing same | |
| CN1233358C (en) | Method for extractings ubstance resisting respiratory syncytial virus from patrinia | |
| CN103735599A (en) | Application of laggera pterodonta extract and composition in drug for resisting influenza A virus | |
| CN101347492A (en) | Use of Trigonostemon xyphophylloides extract in preparing anti-AIDS medicament | |
| CN109771465B (en) | Traditional Chinese medicine effective part composition with significant HIV/SIV inhibition effect | |
| CN1051470C (en) | Medicine for curing viral hepatitis | |
| CN101584702B (en) | Method of preparing extract of Mallotus apelta and uses for fighting hepatitis B virus | |
| CN101045073A (en) | Method for preparing extractive of liuyueqing and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060816 Termination date: 20100420 |